D. E. Shaw & Co. Inc. Takes $281,000 Position in Stevanato Group S.p.A. (NYSE:STVN)

D. E. Shaw & Co. Inc. purchased a new position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,900 shares of the company's stock, valued at approximately $281,000.

A number of other institutional investors have also recently added to or reduced their stakes in STVN. TimesSquare Capital Management LLC boosted its position in Stevanato Group by 114.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company's stock worth $71,657,000 after purchasing an additional 1,756,100 shares during the period. Jennison Associates LLC purchased a new position in Stevanato Group in the 4th quarter valued at about $20,239,000. Mutual of America Capital Management LLC purchased a new position in Stevanato Group in the 4th quarter valued at about $13,848,000. Ranger Investment Management L.P. purchased a new position in Stevanato Group in the 4th quarter valued at about $12,940,000. Finally, Artisan Partners Limited Partnership boosted its position in Stevanato Group by 28.7% in the 4th quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company's stock valued at $51,333,000 after buying an additional 524,989 shares during the last quarter.

Analyst Upgrades and Downgrades

STVN has been the subject of a number of analyst reports. Stephens raised shares of Stevanato Group to a "strong-buy" rating in a research report on Monday, April 21st. UBS Group cut their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Finally, William Blair restated an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of €25.70 ($29.20).

Stevanato Group Stock Down 1.2%

Shares of Stevanato Group stock traded down €0.28 ($0.32) during trading on Thursday, reaching €22.91 ($26.03). The company had a trading volume of 181,300 shares, compared to its average volume of 339,493. The company has a market cap of $6.94 billion, a price-to-earnings ratio of 48.74, a price-to-earnings-growth ratio of 7.18 and a beta of 0.51. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.82) and a fifty-two week high of €25.75 ($29.26). The firm's fifty day moving average is €21.77 and its 200-day moving average is €21.33. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share for the quarter, hitting the consensus estimate of €0.20 ($0.23). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. On average, analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be paid a $0.0613 dividend. The ex-dividend date of this dividend is Thursday, June 5th. This is an increase from Stevanato Group's previous annual dividend of $0.05. This represents a dividend yield of 0.3%. Stevanato Group's payout ratio is currently 11.76%.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.